Summary
120.83 0.41(0.34%)08/30/2024
Novartis AG (NVS)
Novartis AG (NVS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.35 | 1.92 | 7.97 | 19.99 | 18.36 | 18.57 | 44.23 | 871.93 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 120.83 | |
| Open | 120.37 | |
| High | 120.92 | |
| Low | 120.06 | |
| Volume | 838,272 | |
| Change | 0.42 | |
| Change % | 0.35 | |
| Avg Volume (20 Days) | 821,796 | |
| Volume/Avg Volume (20 Days) Ratio | 1.02 | |
| 52 Week Range | 92.19 - 120.92 | |
| Price vs 52 Week High | -0.07% | |
| Price vs 52 Week Low | 31.07% | |
| Range | 0.38 | |
| Gap Up/Down | -0.43 | |
Fundamentals | ||
| Market Capitalization (Mln) | 236,520 | |
| EBIDTA | 18,944,000,000 | |
| PE Ratio | 23.2045 | |
| PEG Ratio | 5.0912 | |
| WallStreet Target Price | 114.51 | |
| Book Value | 19.4450 | |
| Earnings Per Share | 4.4000 | |
| EPS Estimate Current Quarter | 1.6700 | |
| EPS Estimate Next Quarter | 1.8100 | |
| EPS Estimate Current Year | 7.2700 | |
| EPS Estimate Next Year | 8.0300 | |
| Diluted EPS (TTM) | 4.4000 | |
| Revenues | ||
| Profit Marging | 0.3194 | |
| Operating Marging (TTM) | 0.3078 | |
| Return on asset (TTM) | 0.0865 | |
| Return on equity (TTM) | 0.1983 | |
| Revenue TTM | 47,732,998,144 | |
| Revenue per share TTM | 23.1680 | |
| Quarterly Revenue Growth (YOY) | 0.0970 | |
| Quarterly Earnings Growth (YOY) | 0.2150 | |
| Gross Profit (TTM) | 36,744,000,000 | |
| Dividends | ||
| Dividend Share | 3.9190 | |
| Dividend Yield | 0.0370 | |
| Valuations | ||
| Trailing PE | 23.2045 | |
| Forward PE | 13.2450 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.0962 | |
| Revenue Enterprise Value | 4.4105 | |
| EBITDA Enterprise Value | 11.2733 | |
| Shares | ||
| Shares Outstanding | 2,040,409,984 | |
| Shares Float | 1,949,077,797 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 6.98 | |
08/29 10:51 EST - zacks.com
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
08/28 01:15 EST - globenewswire.com
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol (LDL-C) lowering versus both placebo and ezetimibe in patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease (ASCVD) and not receiving lipid-lowering therapy1.
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol (LDL-C) lowering versus both placebo and ezetimibe in patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease (ASCVD) and not receiving lipid-lowering therapy1.
08/26 10:21 EST - investors.com
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
08/24 08:14 EST - reuters.com
Siemens Healthineers to buy Novartis unit for over $223 million, FT reports
Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Saturday.
Siemens Healthineers to buy Novartis unit for over $223 million, FT reports
Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Saturday.
08/19 13:57 EST - invezz.com
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.
08/18 10:45 EST - fool.com
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
Despite DexCom's recent challenges, it still has ample growth opportunities. Novartis is a reliable dividend payer that recently changed its business for the better.
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
Despite DexCom's recent challenges, it still has ample growth opportunities. Novartis is a reliable dividend payer that recently changed its business for the better.
08/15 11:20 EST - zacks.com
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.
08/12 15:58 EST - reuters.com
Novartis loses initial bid to block generic of best-selling heart drug
Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday.
Novartis loses initial bid to block generic of best-selling heart drug
Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday.
08/10 07:00 EST - seekingalpha.com
10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next
Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the market decline might still have another 8%. Dividend aristocrats are down just 0.9% in this downturn, and many aristocrats are up modestly.
10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next
Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the market decline might still have another 8%. Dividend aristocrats are down just 0.9% in this downturn, and many aristocrats are up modestly.
08/07 19:38 EST - prnewswire.com
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p
08/07 14:23 EST - reuters.com
US FDA approves Novartis' kidney disease drug
The U.S. Food and Drug Administration has approved the use of Novartis' drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday.
US FDA approves Novartis' kidney disease drug
The U.S. Food and Drug Administration has approved the use of Novartis' drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday.
08/05 16:43 EST - reuters.com
Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
07/24 08:02 EST - businesswire.com
Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer.
Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer.
07/20 03:50 EST - seekingalpha.com
Novartis: Another Beat, Another Raise
The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer drug launches. Novartis raised the 2024 core operating income guidance. Our buy rating is then confirmed.
Novartis: Another Beat, Another Raise
The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer drug launches. Novartis raised the 2024 core operating income guidance. Our buy rating is then confirmed.
07/19 10:15 EST - seekingalpha.com
Why Novartis Deserves Your Attention After Q2 2024 Results
On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year, primarily due to strong sales of its oncology franchise. So, Kisqali sales amounted to $717 million for the three months ended June 30, 2024, an increase of 45.4% year-on-year.
Why Novartis Deserves Your Attention After Q2 2024 Results
On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year, primarily due to strong sales of its oncology franchise. So, Kisqali sales amounted to $717 million for the three months ended June 30, 2024, an increase of 45.4% year-on-year.
07/19 08:55 EST - marketbeat.com
Pharma Leader Beats on Earnings, But Shares Fall
Novartis NYSE: NVS is the seventh largest pharmaceutical company in the world, and is based in Switzerland. The firm reported Q2 2024 financial results on Jul. 18, 2024.
Pharma Leader Beats on Earnings, But Shares Fall
Novartis NYSE: NVS is the seventh largest pharmaceutical company in the world, and is based in Switzerland. The firm reported Q2 2024 financial results on Jul. 18, 2024.
07/18 18:23 EST - youtube.com
Novartis expects 'strong momentum' going into second half, says CEO Vasant Narasimhan
Vasant Narasimhan, Novartis CEO, joins CNBC's Angelica Peebles on 'The Exchange' to discuss Q2 earnings, reception of its prostate cancer drug, and more.
Novartis expects 'strong momentum' going into second half, says CEO Vasant Narasimhan
Vasant Narasimhan, Novartis CEO, joins CNBC's Angelica Peebles on 'The Exchange' to discuss Q2 earnings, reception of its prostate cancer drug, and more.
07/18 14:15 EST - fool.com
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
Drugmaker Novartis' second-quarter results were better than expected. Profit guidance for the remainder of the year was also raised.
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
Drugmaker Novartis' second-quarter results were better than expected. Profit guidance for the remainder of the year was also raised.
07/18 10:51 EST - investopedia.com
Novartis Falls Despite Earnings Beat, Guidance Raise
Novartis (NVS) American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and raised its full-year core operating income guidance.
Novartis Falls Despite Earnings Beat, Guidance Raise
Novartis (NVS) American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and raised its full-year core operating income guidance.